Alternate-day oral therapy with Nalfurafine hydrochloride as refractory pruritus for liver cirrhotic patients

Alternate-day oral therapy with Nalfurafine hydrochloride as refractory pruritus for liver cirrhotic patients - Alternate-day therapy with Nalfurafine hydrochloride

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023638

Enrollment

Registered

2016-08-16

Start date

2016-08-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Nalfurafine hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Intractable pruritus in patients with liver cirrhosis of Child-Pugh class B

Exclusion criteria

Exclusion criteria: Patients who are regarded as inappropriate to participate the study

Design outcomes

Primary

Measure	Time frame
To assess the rate of accomplish of alternate-day oral therapy with Nalfurafine hydrochloride	—

Secondary

Measure	Time frame
1)To determine the plasma concentration of Nalfurafine hydrochloride during alternate-day oral therapy 2)To investigate the therapeutic effect according to gene polyrmorphism of OPRM1.	—

Countries

Japan

Contacts

Public ContactTakahama

Juntendo University Center of study driving

rinri@juntendo.ac.jp03-3813-3176

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026